Neumora Therapeutics (NMRA) Other financing activities (2022 - 2025)

Neumora Therapeutics' Other financing activities history runs 4 years deep, the most recent figure standing at $216000.0 for Q4 2025.

• On a quarterly basis, Other financing activities fell 82.4% year-over-year to $216000.0 in Q4 2025; TTM through Dec 2025 was $275000.0, a 96.32% decrease from a year earlier, with the FY2025 full-year figure at $275000.0, down 96.32% from the prior year.
• Other financing activities improved to $216000.0 in Q4 2025 per NMRA's latest filing, from $59000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $230.0 million in Q4 2023 and bottomed at $42000.0 in Q4 2022.
• The 4-year median for Other financing activities is $1.2 million (2024), against an average of $21.9 million.
• Across the five-year window, Other financing activities surged 547633.33% in 2023 and tumbled 99.47% in 2024, its largest moves.
• Year by year, Other financing activities stood at $42000.0 in 2022, then jumped by 547633.33% to $230.0 million in 2023, then tumbled by 99.47% to $1.2 million in 2024, then sank by 82.4% to $216000.0 in 2025.
• Per Business Quant, the three latest NMRA Other financing activities figures stand at $216000.0 (Q4 2025), $59000.0 (Q2 2025), and $1.2 million (Q4 2024).